ACA
PBYI icon

Acorn Capital Advisors’s Puma Biotechnology PBYI Stock Holding History

Acorn Capital Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$26.4M Hold
4,131,299
– – 7.5% 4
2025
Q4 		$24.6M Hold
4,131,299
– – 8.33% 5
2025
Q3 		$21.9M Hold
4,131,299
– – 11.14% 3
2025
Q2 		$14.2M Buy
4,131,299
+191,247
+5% +$610K 9.27% 4
2025
Q1 		$11.7M Hold
3,940,052
– – 7.78% 6
2024
Q4 		$12M Buy
+3,940,052
New +$11.5M 6.47% 5

Other funds holding PBYI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
OSAM
O'Shaughnessy Asset Management Stamford, Connecticut $20.1B AUM 30.42% 1-Year Est. Return

Acorn Capital Advisors's PBYI Position: Q1 2026 in Review

Acorn Capital Advisors held its Puma Biotechnology (PBYI) position steady in Q1 2026 at 4,131,299 shares worth $26.4M. The position accounts for 7.5% of the portfolio, ranked #4.

Acorn Capital Advisors first reported a position in PBYI in Q4 2024 and has held it in 6 quarters since. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • Acorn Capital Advisors held 4,131,299 shares of Puma Biotechnology worth $26.4M as of Q1 2026.
  • Acorn Capital Advisors left its Puma Biotechnology share count unchanged in Q1 2026.
  • Puma Biotechnology made up 7.5% of Acorn Capital Advisors's portfolio in Q1 2026, its #4 holding.
  • Acorn Capital Advisors first reported a position in Puma Biotechnology in Q4 2024 and has held it in 6 quarters since.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.